Recently, much effort has been put into research. Advances in... Congestive Heart Failure Care. How is CHF diagnosed? 2.
|
|
- Victor Houston
- 5 years ago
- Views:
Transcription
1 Advances in... Congestive Heart Failure Care Heart failure can currently be considered an epidemic. The article discusses some of the recent advances in outpatient management of congestive heart failure. Michael C.Y. Chan, MBBS, FRCPC, FACC; and Rosa Gutierrez, MN, NP Fact Box: Did you know? It is estimated 1.5% to 2% of the general population has congestive heart failure (CHF). Mortality due to CHF is around 50% five years after initial diagnosis. Cardiovascular disease, including CHF, is the number one cause of death in North America. CHF is one of the leading reasons for admission to hospital in Canada and the number one cause of hospitalization in people over 65. Recently, much effort has been put into research and development of evidence-based practice guidelines for congestive heart failure (CHF) diagnosis and treatment. 1 In the updated American College of Cardiology heart failure guidelines, 2 there is a new classification to emphasize early recognition and treatment of CHF. It is now appropriate to start pharmacotherapy and risk factor modification even before symptoms manifest or before detection of structural heart disease. How is CHF diagnosed? 1. Echocardiography CHF is mostly a clinical diagnosis and is relatively easy when the typical symptoms and signs are present. However, these symptoms and signs are not always present. Echocardiography should be obtained whenever CHF is suspected or even when it is confirmed. This test can often give clues to etiology, severity of structural heart disease and concomitant pathology. With most modern machines, the diastolic function and right and left heart filling pressures can often be estimated and may be a guide to treatment as well. 2. Diastolic CHF One-third to one-half of patients with CHF symptoms have preserved systolic function (ejection fraction [EF] > 45% to 50%) and no significant valve abnormalities on echocardiography. Diastolic CHF is one of the several terms proposed to define this condition. Although the overall prognosis of diastolic CHF is better than CHF with systolic dysfunction, the survival is less than that of the normal population. The most common etiologies are thought to be hypertension and coronary artery disease (CAD). Patients should be prescribed diuretics for symptom relief and the underlying conditions should be treated. 3. Diagnosing CAD CAD is the most common etiology of CHF; therefore, in all paients diagnosed with CHF, a careful history should be obtained for any history of angina-like symptoms and for any risk factors for CAD. If the history is suspicious, a cardiac perfusion imaging study, such as MIBI or thallium scan, should be obtained. If there is severe or unstable angina, or recently diagnosed myocardial infarction, consider going directly to coronary angiography. 26 Perspectives in Cardiology / February 2005
2 Table 1 CHF patients who should be admitted to hospital Severe decompensated CHF Severe symptomatic hypotension Poor perfusion states Shock Severe worsening creatinine Active ischemia Table 2 Measures to reduce frequency of readmission of CHF patients Correct etiologic and precipitating factors Start angiotensin-converting enzyme inhibitors and beta blockers before discharge Educate patient and family about medications, diet (limiting sodium intake), recognizing precipitating factors and suitable activity level Follow-up within 1-2 weeks Continue to monitor weight, electrolytes, renal function Ensure patient compliance with treatment Possible home nurse visit 4. BNP B-type natriuretic peptide (BNP) is released from the cardiac ventricles in response to increased wall tension. In the clinical setting, if unsure about the cause of dyspnea, the following ranges may be used to help with diagnosis: 1. BNP < 100 pg/ml: 0% to 2% probability of CHF; other etiologies have to be sought 2. BNP > 500 pg/ml: CHF very likely (95%); in most instances, need to admit to hospital for treatment 3. Grey zone, 100 pg/ml to 500 pg/ml: Need to workup; usually from RV strain Although there is strong evidence for the value of BNP in the evaluation of dyspnea of uncertain cause, further studies are needed before the widespread use of BNP is recommended. How is CHF treated? Certain patients suspected of having CHF should be admitted to hospital (Table 1). During hospitalization, specific measures should be taken to reduce the frequency of readmission (Table 2). The following is recommended for both inpatients and outpatients: 1. Diuretics Diuretics should only be used for congestive symptoms. Patients who do not have fluid overloaded may require only a small dose of diuretics or none at all. The patient s weight and jugular venous pulse are useful for assessing fluid status. The presence of ankle edema indicates fluid overload, but lack of edema does not rule it out. Patients whose diuretic dose is changed must have electrolytes and renal About the author... Dr. Chan is an associate clinical professor of medicine, University of Alberta, and the co-director, Heart Function Stabilization Program, Royal Alexandra Hospital, Edmonton, Alberta. About the author... Ms. Gutierrez is a cardiac nurse practitioner specializing in heart failure, and the co-ordinator, Heart Function Stabilization Program, Royal Alexandra Hospital, Edmonton, Alberta. Perspectives in Cardiology / February
3 function checked within a few days to a week of the change. 2. ACE inhibitors and ARBs The recently published CHARM study is the only well-performed, randomized control trial for treatment of diastolic CHF. 3 In one arm of the study, patients with New York Heart Association functional class II-IV CHF and LVEF > 40% were randomized to the angiotensin receptor blocker (ARB), candesartan, 32 mg once daily, or placebo. After a median followup of 36.6 months, cardiovascular death did not differ between groups, but fewer patients in the candesartan group were admitted to hospital for CHF. Therefore, an ARB, in addition to diuretics, should be considered for treatment of diastolic CHF. Other arms of the CHARM study, as well as the VALIANT study, 4 did not show definite superiority of ARBs over angiotensin-converting enzyme (ACE) inhibitors; therefore, ACE inhibitors should still be first choice for HF treatment. In patients who are intolerant to ACE inhibitors, ARBs can be used. An ARB may also be used if the patient is already on a maximum dose of ACE inhibitor, but still symptomatic and/or relatively hypertensive. Note that ACE inhibitors and ARBs share some common adverse effects, such as hyperkalemia, rise in creatinine and hypotension. 3. Spironolactone The landmark RALES paper established the role of spironolactone, as a therapy that can lower mortality in classes III and IV CHF patients. One adverse effect of spironolactone is hyperkalemia; however, this effect can be avoided (Table 3) Beta blockers Table 3 Avoiding hyperkalemia in CHF patients Start low-dose ACE inhibitor or ARB Do not exceed spironolactone, 25 mg QD Measure potassium and creatinine one week after starting or increasing ACE inhibitor/arb/ spironolactone; check potassium every month thereafter for 3 months If potassium > 5.5 mmol/l, stop ACE inhibitor/arb/sprironolactone If potassium is 5.0 to 5.5, lower doses of drugs (especially the spironolactone) Avoid spironolactone in patients with creatinine > 250 mmol/l (or GFR < 30mL/min), potassium > 5.5 mmol/l (irreversible) Use spironolactone only in systolic CHF (classes III, IV) Limit dietary intake of potassium (e.g., orange, tomato, melon, banana, certain herbs, etc.) Use loop diuretics concommitantly Consider using sodium bicarbonate, 650 mg tabs orally twice daily Avoid non-steroidal anti-inflammatories and COX-2 inhibitors Be cautious in older patients, women and those with diabetes ACE: Angiotensin-converting enzyme ARB: Angiotensin receptor blocker QD: Every day GFR: Glomerular filtration rate COX: Cyclooxygenase Beta blockers are indicated when EF < 45%, in addition to ACE inhibitors/arbs with diuretics, as needed to control symptoms. It is recommended to start beta blockers before discharge for patients admitted for decompensated CHF. The key is to make sure the patient has been adequately diuresed and is clinically stable, with electrolytes and creatinine in the acceptable range. In contrast to traditional teaching, beta blockers should be used in conditions such as diabetes, chronic obstructive pulmonary disease and peripheral vascular disease. Of course, great caution should be exercised in patients with recurrent hypoglycemia and asthma. Cont d on page Perspectives in Cardiology / February 2005
4 Beta blockers should be started at a low dose with monitoring of blood pressure, electrolytes, renal function and any increase in dyspnea. In the office, the beta blocker should be up-titrated every two to four weeks, with monitoring of blood pressure, symptoms of lightheadedness, dyspnea, fluid overload and symptomatic bradycardia. ACE inhibitor and/or diuretic dosages may have to be adjusted to allow up-titration of the beta blocker. 1/3 to 1/2 of patients with CHF symptoms have preserved systolic function and no significant valve abnormalities on echocardiography. 5. Digoxin Digoxin should be considered for patients who have persistent symptoms of CHF despite therapy with diuretics, ACE inhibitors and a beta blocker, when the CHF is caused by systolic dysfunction. Digoxin should not be used for stabilization of patients with acutely decompensated CHF. The dosage of digoxin should be mg daily in most patients, with lower doses being used in patients over 70, those with impaired renal function or those with a low lean body mass. Loading doses of digoxin are not necessary. The serum digoxin level should not be used to titrate up to a therapeutic level; rather, it should be used in patients suspected to have digoxin toxicity. In a post-hoc analysis of the DIG study, serum digoxin levels > 1.2 ng/ml were associated with increased mortality. It is now suggested digoxin may be more effective and safer in the range of 0.5 ng/ml to 0.8 ng/ml.
5 6. Nitrate/hydralazine A recent study showed a nitrate/hydralazine combination reduced mortality in patients with CHF. 6 Whether these results are applicable to the general population of patients with CHF is still under discussion. However, in patients who are intolerant to ACE inhibitors and ARBs, it is reasonable to use nitrate/hydralazine as vasodilators. What about device therapy? ICD Recent studies, including the SCD-Heft study, 7 have shown prophylactic implantation of implantable cardiovertor defibrillator (ICD) in ceratin CHF patients is beneficial in reducing mortality. The 2004 updated Canadian Cardiovascular Society guidelines now suggest considering ICD Take-home message In newly diagnosed CHF patients, start with a diuretic and an ACE inhibitor; an ARB can be used in patients intolerant to ACE inhibitors. Once a patient is stabilized, a beta blocker should be added early on; for sicker patients (class III-IV), add spironolactone, but beware of hyperkalemia. Nonpharmacologic treatments of CHF include reduction of sodium and fluid intake. Consider referral to a cardiologist for advanced therapies (e.g., angioplasty, CRT, implantable defibrillator). implantation in patients who are post ST-elevation myocardial infarct > 3 months and still have EF < 30%. 8 Patients who have a terminal illness with life expectancy < 12 months and those with refractory Cont d on page 32
6 class IV CHF not suitable for heart transplant should not receive ICD. CRT Cardiologists are increasingly implanting cardiac resynchronization (CRT) devices (biventricular pacemakers) in patients who have class III or IV CHF, are on optimal medications and have EF < 35%, QRS > 130 ms and sinus rhythm. These devices have been shown to improve exercise capacity, quality of life and may improve mortality as well. 9 Unfortunately, one-third of patients do not respond to CRT. There is ongoing research to identify patients with "dyssychrony," i.e. who will respond to CRT. What about nonpharmacologic management of CHF? Patients should understand the nature of the disease, etiology, treatmemt, medications, side-effects and most importantly, salt restriction and fluid limitation. One of the most frequent reasons for hospital admissions and emergency visits for CHF patients continues to be excessive intake of salt and fluid. Patients should be encouraged to cook without salt and to read labels when buying processed foods. It is also important to avoid salt substitutes that have potassium instead of sodium. Fluids should be limited to six to eight cups a day. Exercise in patients with CHF is safe and improves fitness and quality of life. Any patient with stable symptoms should be encouraged to walk daily or participate in low-intensity activities. PCard References 1. Demers C, Dorian P, Gianetti N, et al: The 2002/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure. Can J Cardiol 2003; 19(4): Hunt SA, Baker DW, Chin MH, et al:acc/aha guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. Circulation 2001; 104(24): Yusuf S, Pfeffer MA, Swedberg K, et al: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003; 362(9386): Pfeffer MA, McMurray JJ,Velazquez EJ, et al:valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349(20): Palmer BF: Managing hyperkalemia caused by inhibitors of the reninangiotensin-aldosterone system. N Engl J Med 2004; 351(6): Taylor AL, Ziesche S,Yancy C, et al: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351(20): Bardy GH, Lee KL, Mark DB, et al: Amiodarone or an implantable cardioverter defibrillator for congestive heart failure. N Engl J Med 2005; 352(3): Armstrong PW, Bogaty P, Buller CE, et al:the 2004 ACC/AHA guidelines:a perspective and adaptation for Canada by the Canadian Cardiovascular Society Working Group. Can J Cardiol 2004; 20(11): Bristow MR, Saxon LA, Boehmer J, et al: Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350(21): Perspectives in Cardiology / February 2005
Heart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationGuideline-Directed Medical Therapy
Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in
More information2016 Update to Heart Failure Clinical Practice Guidelines
2016 Update to Heart Failure Clinical Practice Guidelines Mitchell T. Saltzberg, MD, FACC, FAHA, FHFSA Medical Director of Advanced Heart Failure Froedtert & Medical College of Wisconsin Stages, Phenotypes
More informationChronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationNeprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationChronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More informationHeart Failure Guidelines For your Daily Practice
Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine
More informationTopic Page: congestive heart failure
Topic Page: congestive heart failure Definition: congestive heart f ailure from Merriam-Webster's Collegiate(R) Dictionary (1930) : heart failure in which the heart is unable to maintain an adequate circulation
More informationHeart Failure: Guideline-Directed Management and Therapy
Heart Failure: Guideline-Directed Management and Therapy Guideline-Directed Management and Therapy (GDMT) was developed by the American College of Cardiology and American Heart Association to define the
More informationChronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationCLINICAL PRACTICE GUIDELINE
CLINICAL PRACTICE GUIDELINE Procedure: Congestive Heart Failure Guideline Review Cycle: Biennial Reviewed By: Amish Purohit, MD, MHA, CPE, FACHE Review Date: November 2014 Committee Approval Date: 11/12/2014
More informationPerformance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
More informationThe CCS Heart Failure Companion: Bridging Guidelines to your Practice
The CCS Heart Failure Companion: Bridging Guidelines to your Practice Looking for practical answers concerning optimal heart failure care? The CCS Heart Failure Guidelines Companion can help. The Canadian
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More information8:30-10:30 WS #4: Cardiology :00-13:00 WS #11: Cardiology 101 (Repeated)
Professor Ralph Stewart Cardiologist Auckland City Hospital Green Lane Cardiovascular Research Unit Auckland Heart Group Fiona Stewart Cardiologist Green Lane Hospital National Women's Hospital Professor
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure
ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More informationHeart Failure. Jay Shavadia
Heart Failure Jay Shavadia Definition Clinical syndrome characterized by: Symptoms: breathlessness at rest or on exercise, fatigue, tiredness or ankle swelling AND Signs: tachycardia, tachypnea, pulmonary
More informationIntroduction to Heart Failure. Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL
Introduction to Heart Failure Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL Disclosures No relevant financial relationships to disclose Objectives and Outline Define heart
More informationCT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD
CT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD Clinical syndrome resulting from a structural or functional cardiac disorder that impairs the ability of the heart to
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More information2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure Developed in Collaboration With the American Academy of Family Physicians, American College of Chest
More informationHeart Failure. Dr. William Vosik. January, 2012
Heart Failure Dr. William Vosik January, 2012 Questions for clinicians to ask Is this heart failure? What is the underlying cause? What are the associated disease processes? Which evidence-based treatment
More informationSummary/Key Points Introduction
Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification
More informationHEART FAILURE. Heart Failure in the US. Heart Failure (HF) 3/2/2014
HEART FAILURE Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center March 2014 Heart Failure in the US Prevalence - ~5 million 650,000 new cases annually 300,000 deaths annually Leading
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationMEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION FRANCIS X. CELIS, D.O. OPSO FALL CONFERENCE PORTLAND, OR 16 SEPTEMBER 2017 OVERVIEW What are the ACC/AHA Stages of HF? What
More informationIncidence. 4.8 million in the United States. 400,000 new cases/year. 20 million patients with asymptomatic LV dysfunction
Heart Failure Diagnosis According to the Working Group in Heart Failure, CHF is a syndrome where the diagnosis has the following essential components: A combination of: Symptoms, typically breathlessness
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationNora Goldschlager, M.D. SFGH Division of Cardiology UCSF
CLASSIFICATION OF HEART FAILURE Nora Goldschlager, M.D. SFGH Division of Cardiology UCSF DISCLOSURES: NONE CLASSIFICATION C OF HEART FAILURE NYHA I IV New paradigm Stage A: Pts at high risk of developing
More informationDiagnosis and management of Chronic Heart Failure in 2018: What does NICE say? PCCS Meeting Issues and Answers Conference Nottingham
Diagnosis and management of Chronic Heart Failure in 2018: What does NICE say? PCCS Meeting Issues and Answers Conference Nottingham NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Chronic heart failure
More informationAF in the ER: Common Scenarios CASE 1. Fast facts. Diagnosis. Management
AF in the ER: Common Scenarios Atrial fibrillation is a common problem with a wide spectrum of presentations. Below are five common emergency room scenarios and the management strategies for each. Evan
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationRate of Heart failure guideline adherence in a tertiary care center in India after accounting for the therapeutic contraindications.
Article ID: WMC004618 ISSN 2046-1690 Rate of Heart failure guideline adherence in a tertiary care center in India after accounting for the therapeutic contraindications. Peer review status: No Corresponding
More informationMedical Management of Acute Heart Failure
Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training
More informationOptimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists
Optimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists Old Drugs for an Old Problem Jay Geoghagan, MD, FACC BHHI Primary Care Symposium February 28, 2014 None. Financial disclosures
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationChronic. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Michael G. Shlipak, MD, MPH
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationOutline. Chronic Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.
Chronic Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center Scientific
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationDrugs acting on the reninangiotensin-aldosterone
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationMedical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011
Medical Treatment for acute Decompensated Heart Failure Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011 2010 HFSA guidelines for ADHF 2009 focused update of the 2005 American College
More informationHeart.org/HFGuidelinesToolkit
2017 /H/HFS Focused Update of the 2013 F/H 6.3.1 Biomarkers for Prevention: Recommendation OR LOE Recommendation a For patients at risk of developing HF, natriuretic peptide biomarker-based screening followed
More informationImplantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure Wojciech Zareba Postinfarction patients with left ventricular dysfunction are at increased risk
More informationManagement Strategies for Advanced Heart Failure
Management Strategies for Advanced Heart Failure Mary Norine Walsh, MD, FACC Medical Director, HF and Cardiac Transplantation St Vincent Heart Indianapolis, IN USA President American College of Cardiology
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationDiastolic Heart Failure. Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012
Diastolic Heart Failure Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012 Disclosures Have spoken for Merck, Sharpe and Dohme Sat on a physician advisory
More informationESC Guidelines. ESC Guidelines Update For internal training purpose. European Heart Journal, doi: /eurheart/ehn309
ESC Guidelines Update 2008 ESC Guidelines Heart failure update 2008 For internal training purpose. 0 Agenda Introduction Classes of recommendations Level of evidence Treatment algorithm Changes to ESC
More informationAtrial fibrillation (AF) is a disorder seen
This Just In... An Update on Arrhythmia What do recent studies reveal about arrhythmia? In this article, the authors provide an update on atrial fibrillation and ventricular arrhythmia. Beth L. Abramson,
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More information2/3/2017. Objectives. Effective Heart Failure Management through Evidence Based Practice and Innovation
Effective Heart Failure Management through Evidence Based Practice and Innovation Jennifer Bauerly RN, CHFN, APRN-BC CentraCare Heart and Vascular Center Objectives Describe the scope and impact of heart
More informationGerasimos Filippatos MD, FESC, FCCP, FACC
Gerasimos Filippatos MD, FESC, FCCP, FACC Head of HF Unit at Athens University Hospital, Greece President (2014-2016) of the HF Association of the European Society of Cardiology (ESC) Served as Chair of
More informationHeart Failure Management Policy and Procedure Phase 1
1301 Punchbowl Street, Harkness Suite 225 Honolulu, Hawaii 96813 Phone (808) 691-7220 Fax: (808) 691-4099 www.queenscipn.org Policy and Procedure Phase 1 Policy Number: Effective Date: Revised: Approved
More informationHeart Failure Update. Bibiana Cujec MD May 2015
Heart Failure Update Bibiana Cujec MD May 2015 Disclosures Participation in clinical trial GUIDE IT (BNP in management of HF) Plan Review of new trials/ccs guidelines Management of heart failure: cases
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationHeart Failure Treatments
Heart Failure Treatments Past & Present www.philippelefevre.com Background Background Chronic heart failure Drugs Mechanical Electrical Background Chronic heart failure Drugs Mechanical Electrical Sudden
More informationI have no disclosures. Disclosures
I have no disclosures Disclosures What is Heart Failure? Heart Failure (HF) A complex clinical syndrome where patients present with symptoms (i.e. dyspnea, fatigue, fluid retention) that result from any
More informationARNI (Angiotensin Receptor blocker / Neprilysin Inhibitors [Sacubutril/Valsartan]) Heart Failure Medication Initiation and Titration
ARNI (Angiotensin Receptor blocker / Neprilysin Inhibitors [Sacubutril/Valsartan]) Heart Failure Medication and Symptomatic HF despite ACEI/ARB and B-blocker therapy Bilateral renal artery stenosis Moderate/Severe
More informationHeart. Severe. Failure. Congestive heart failure (CHF) is very. What you can do for your patients
Focus on CME at the University of Université Manitoba de Sherbrooke By Anne Fradet, MD, FRCP, CSPQ Severe Heart Failure What you can do for your patients The case of Mr. White Mr. White, 72, comes to your
More informationImplementing the CardioMEMS HF System into the Management of Heart Failure Patients
Implementing the CardioMEMS HF System into the Management of Heart Failure Patients Robert W. Hull MD FACC Associate Professor of Medicine WVU Heart Institute Co-director, Arrhythmia Service Director,
More informationWhat s new in 2016 Guidelines of the European Society of Cardiology? HEART FAILURE. Marc Ferrini (Lyon Fr)
What s new in 2016 Guidelines of the European Society of Cardiology? HEART FAILURE Marc Ferrini (Lyon Fr) Palermo (I) 1 04 2017 Consulting Fees, Honoraria: BAYER PHARMA BOEHRINGER INGELHEIM BRISTOL MEYERS
More informationHeart Failure Management: Continuum of Care
Healthy Kingsport Conference Heart Failure Management: Continuum of Care Robin Harris PhD, ANP-BC, ACNS-BC Clinical Assistant Professor University of Tennessee College of Nursing Important Info I, Robin
More informationWhat s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine
What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine Current Guideline of Treatment Asymptomatic Mild/Mod Severe Refractory Correct Cause: Arrhythmias
More informationObjectives. Outline 4/3/2014
Jessica Litke PGY1 ISHP Spring Meeting April 12, 2014 Objectives Appreciate the significance of heart failure (HF) to a patient and to the health care system Understand 2013 ACCF/AHA guidelines for the
More informationCardiovascular Clinical Practice Guideline Pilot Implementation
Cardiovascular Clinical Practice Guideline Pilot Implementation Pharmacologic Management of Chronic Heart Failure Sept 15, 2004 Angela Allerman, PharmD, BCPS DoD Pharmacoeconomic Center Promoting high
More informationThe Management of Heart Failure after Biventricular Pacing
The Management of Heart Failure after Biventricular Pacing Juan M. Aranda, Jr., MD University of Florida College of Medicine, Division of Cardiovascular Medicine, Gainesville, Florida Approximately 271,000
More informationDiagnosis & Management of Heart Failure. Abena A. Osei-Wusu, M.D. Medical Fiesta
Diagnosis & Management of Heart Failure Abena A. Osei-Wusu, M.D. Medical Fiesta Learning Objectives: 1) Become familiar with pathogenesis of congestive heart failure. 2) Discuss clinical manifestations
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationDISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE
ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION Lori M. Tam, MD Providence Heart Institute DISCLOSURES NONE 1 OUTLINE Systolic vs. Diastolic Heart Failure New
More informationBalanced information for better care. Heart failure: Managing risk and improving patient outcomes
Balanced information for better care Heart failure: Managing risk and improving patient outcomes Heart failure increases hospitalization Heart failure is the most common medical reason for hospitalization
More informationNew Advances in the Diagnosis and Management of Acute and Chronic Heart Failure
New Advances in the Diagnosis and Management of Acute and Chronic Heart Failure Deborah Budge, MD Intermountain Healthcare Heart Failure Cardiologist Objectives: State the updates from the ACC 2013 HF
More informationLong-Term Care Updates
Long-Term Care Updates July 2015 By Amy Friedman Wilson, PharmD Heart failure (HF) is a clinical condition in which ventricular filling or ejection of blood is structurally or functionally impaired. 1
More informationContemporary Advanced Heart Failure Therapy
Contemporary Advanced Heart Failure Therapy Andrew Boyle, MD Professor of Medicine Medical Director of Advanced Heart Failure Thomas Jefferson University Philadelphia, PA Audience Response Question 40
More informationHeart Failure Update John Coyle, M.D.
Heart Failure Update 2011 John Coyle, M.D. Causes of Heart Failure Anderson,B.Am Heart J 1993;126:632-40 It It is now well-established that at least one-half of the patients presenting with symptoms and
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationHypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg
Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic
More informationEvaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF<40%
Evaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF
More informationJournal of the American College of Cardiology Vol. 52, No. 24, by the American College of Cardiology Foundation ISSN /08/$34.
Journal of the American College of Cardiology Vol. 52, No. 24, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.09.011
More informationKnown Actions of Digoxin
Known Actions of Digoxin Hemodynamic effects in heart failure Increases cardiac output, no effect on blood pressure Decreases PCWP Increases LVEF (
More informationHeart Failure Therapies State of the Art 2017
Heart Failure Therapies State of the Art 2017 Andrew J. Sauer, MD Assistant Professor Director, Center for Heart Failure Medical Director, Heart Transplantation UNOS Primary Transplant Physician asauer@kumc.edu
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Is there a mortality risk associated with aspirin use in heart failure? Results from a large community based cohort Margaret Bermingham, Mary-Kate Shanahan, Saki Miwa,
More informationUCLA HEART FAILURE CLINICAL PRACTICE GUIDELINE SUMMARY-2005
UCLA HEART FAILURE CLINICAL PRACTICE GUIDELINE SUMMARY-2005 Medical Center Ahmanson-UCLA Cardiomyopathy Center Los Angeles, California Gregg C. Fonarow, MD, Director Ahmanson-UCLA Cardiomyopathy Center
More information